The Wall Street Transcript

The Wall Street Transcript
Share

The Wall Street Transcript

 •  November 30

ViiV Healthcare announces start of phase III study of long-acting cabotegravir for HIV prevention in women The HPTN 084 study will evaluate injections given every two months London, UK 30 November 2017- Today ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced...

The Wall Street Transcript

 •  November 27

PRESS RELEASE ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine The ATLAS-2M study will evaluate injections every two months in virally suppressed patients The ATLAS-2M study is designed to demonstrate the non-inferior antiviral activity, at 48 weeks of treatment,...

The Wall Street Transcript

 •  November 15

Faslodex in combination with abemaciclib showed 16.4 months of progression-free survival (PFS) Second approval in three months expands treatment options for women with HR+, HER2- advanced breast cancer AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a new indication for Faslodex (fulvestrant), expanding the...

BESPONSA is the first and only CD22-directed antibody-drug conjugate indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia EDT Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BESPONSA® (inotuzumab ozogamicin) for the treatment of adults...

Updated analyses of the pivotal Phase 3 POLLUX and CASTOR studies featured as an oral presentation at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting (Abstract 8006) Additionally, Phase 1b findings from the MMY1001 clinical trial assessing daratumumab combination therapy for newly diagnosed patients featured as an oral...

The Wall Street Transcript

 •  May 21, 2015

Retractable Technologies Inc.
Retractable Technologies, Inc. Reports Recognition of Payment
Retractable Technologies, Inc. (NYSE MKT: RVP) ("RTI") reports that in the second quarter of 2015, RTI will record as income and remove from RTI's current liabilities, the $7,724,826 judgment amount previously paid by Becton, Dickinson and Company ("BD") ...

The Wall Street Transcript

 •  May 19, 2015

Medtronic Inc.
Medtronic Announces Preliminary Fourth Quarter and Fiscal Year 2015 Revenue Results
Preliminary Q4 Worldwide Revenue of Approximately $7.3 Billion Grew 7% on a Comparable, Constant Currency Basis; 60% as Reported
Preliminary Q4 U.S. Revenue of Approximately $4.1 Billion Grew 8% on a Comparable Basis; 67% as Reported
Preliminary FY15 ...